Loading…
This event has ended. Visit the official site or create your own event on Sched.
Back To Schedule
Tuesday, June 28 • 2:00pm - 3:15pm
#245: Risk-Based Inspections

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Limited Capacity seats available
Component Type: Session
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

Inspections are a critical component for assuring product quality. The adoption of a risk-based approach to inspections has enabled the integration of product review with traditional inspection criteria and focuses efforts on inspection issues rather than simply on assurance of compliance. This session will highlight ongoing efforts and initiatives geared towards the continuing implementation of risk-based inspections.

Learning Objectives

Discuss related procedural and/or policy challenges and present specific case studies related to risk-based inspections; Identify best practices and ideas for future discussion with regard to risk-based inspections; Identify potential areas for further collaboration on risk-based inspections.

Chair

Mahesh R. Ramanadham, PharmD, MBA

Speaker

Quality Agreements: Defining the Business of Pharmaceutical Quality
Karen Bossert

Integrated Quality Assessment of the Manufacturing Process and Facilities
Robert Iser, MS


Chair
avatar for Mahesh Ramanadham

Mahesh Ramanadham

Division Director (Acting), Div. of Inspectional Assessment, OPF, OPQ, CDER, FDA
Acting Director for the Division of Inspection Assessment within OPQ/OPF. His division is primarily responsible for the center level discipline review of facilities and inspections in support of drug applications. He joined the Agency in November 2009 after graduating with his PharmD... Read More →

Speakers
KB

Karen Bossert

Vice President, Scientific Affairs, Lyophilization Technology, Inc.
Karen Bossert is the Vice-President, Scientific Affairs at Lyophilization Technology, Inc. She has over 25 years of experience in pharmaceutical manufacturing and development. She received her Bachelor of Science degree in Pharmacy and her Doctorate in Pharmaceutics. Karen has authored... Read More →
avatar for Robert Iser

Robert Iser

Acting Director, Office of Process and Facilities, OPQ, CDER, FDA
Bob joined the FDA in 2003. He is currently the acting Director of the Office of Process & Facilities. Prior to the formation of OPQ, Bob was acting Associate Director for Policy Development in OPS. He was also a Division Director and CMC Team Leader in OGD. Prior to joining the FDA... Read More →

Tuesday June 28, 2016 2:00pm - 3:15pm EDT
111AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
  Trk 12: Pharm Quality, Session